IDEXX Laboratories, Inc. $IDXX Shares Sold by Sumitomo Mitsui Trust Group Inc.

Key Points

• Sumitomo Mitsui Trust Group reduced its IDEXX Laboratories stake by 3.7% in the third quarter, selling 7,284 shares and retaining 189,012 shares worth about $98.7 million. Institutional investors collectively own 87.84% of the company.
• IDEXX beat third-quarter earnings and revenue expectations, reporting $3.96 per share and $1.21 billion in revenue, with recurring diagnostic revenue increasing approximately 11% year over year.
• Management raised its full-year 2026 guidance, supporting a “Moderate Buy” analyst consensus and $721.67 average price target. However, softer veterinary visit volumes and margin pressure remain risks.

Sumitomo Mitsui Trust Group Inc. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 189,012 shares of the company's stock after selling 7,284 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.24% of IDEXX Laboratories worth $98,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Aurora Investment Managers LLC. purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $2,442,000. National Pension Service increased its stake in shares of IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company's stock worth $68,071,000 after buying an additional 6,885 shares during the period. NewEdge Advisors LLC increased its stake in shares of IDEXX Laboratories by 60.9% in the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company's stock worth $8,552,000 after buying an additional 5,761 shares during the period. Arizona State Retirement System increased its stake in shares of IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company's stock worth $11,988,000 after buying an additional 1,074 shares during the period. Finally, Howard Capital Management LLC bought a new stake in IDEXX Laboratories during the 3rd quarter valued at $1,249,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories News Roundup

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
• Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
• Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
• Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
• Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Jefferies Financial Group decreased their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a "buy" rating on the stock in a research report on Tuesday, October 20th. JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating for the company in a research note on Friday, October 16th. The Goldman Sachs Group initiated coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They set a "buy" rating and a $740.00 price objective for the company. Finally, Leerink Partners dropped their target price on shares of IDEXX Laboratories from $725.00 to $715.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $721.67.

IDEXX Laboratories Price Performance

IDXX opened at $671.64 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The stock has a market capitalization of $52.91 billion, a PE ratio of 47.23 and a beta of 1.55. The stock's 50 day moving average price is $536.56 and its 200-day moving average price is $573.88.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping analysts' consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter last year, the firm posted $3.22 earnings per share. The firm's revenue was up 9.9% on a year-over-year basis. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.79% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.